

**UNIVERSITI SAINS MALAYSIA
GERAN PENYELIDIKAN UNIVERSITI PENYELIDIKAN
LAPORAN AKHIR**

**CB1 CANNABINOID RECEPTOR IN BRAIN MESOLIMBIC
SYSTEM OF MITRAGYNE-SENSITISED ALBINO WASTAR
RATS AS A CANDIDATE MOLECULAR TARGET IN
MITRAGYNA SPECIOSA (KETUM) ADDICTION**

PENYELIDIK

DR. MUZAIMI MUSTAPHA

PENYELIDIK BERSAMA

**PROF. SHARIF MAHSUFI MANSOR
PROF. JAFRI MALIN ABDULLAH
PROF. HASNAN JAAFAR
NURUL IMAN WAN ISMAIL**

2015

BORANG FRGS – P3(R)



KEMENTERIAN PENDIDIKAN MALAYSIA

FINAL REPORT FUNDAMENTAL RESEARCH GRANT SCHEME (FRGS)

Laporan Akhir Skim Geran Penyelidikan Fundamental (FRGS)
Pindaan 2/2013

A RESEARCH TITLE : CB1 Cannabinoid Receptor in Brain Mesolimbic System of Mitragynine-Sensitised Albino Swiss mice as a candidate molecular targets in *Mitragyna speciosa* (Ketum) Addiction

PHASE & YEAR : 2/2010

START DATE : 1 April 2011

END DATE : 31 Mac 2013

EXTENSION PERIOD (DATE) : 30 September 2013

PROJECT LEADER: DR MUZAIMI MUSTAPHA

PROJECT MEMBERS: 1. Profesor Sharif Mahsufi Mansor
(including GRA) 2. Profesor Jafri Malin Abdullah
3. Profesor Hasnan Jaafar
4. Nurul Iman Wan Ismail

PROJECT ACHIEVEMENT

B ACHIEVEMENT PERCENTAGE					
Project progress according to milestones achieved up to this period		0 - 50%		51 - 75%	
Percentage (please state #%)				95%	
RESEARCH OUTPUT					
Number of articles/ manuscripts/ books (Please attach the First Page of Publication)		Indexed Journal		Non-Indexed Journal	
		1			
Conference Proceeding (Please attach the First Page of Publication)		International		National	
		1			
Intellectual Property (Please specify)		Nil			
HUMAN CAPITAL DEVELOPMENT					
Human Capital	Number				Others (please specify)
	On-going		Graduated		
Citizen	Malaysian	Non Malaysian	Malaysian	Non Malaysian	
PhD Student					
Master Student	1				
Undergraduate Student					
Total	1				

EXPENDITURE (Perbelanjaan)

C Budget Approved (*Peruntukan diluluskan*) : RM 68,000
Amount Spent (*Jumlah Perbelanjaan*) : RM 67365.24
Balance (*Baki*) : RM 634.76
Percentage of Amount Spent : 99.1%
(*Peratusan Belanja*)

**ADDITIONAL RESEARCH ACTIVITIES THAT CONTRIBUTE TO ACQUISITION OF TECHNICAL, SOFT AND HARDSKILLS
(Aktiviti Penyelidikan Tambahan yang menyumbang kepada perolehan kemahiran teknikal, kemahiran lembut dan kemahiran keras)**

D	International		
	Activity	Date (Month, Year)	Organizer
	Oral Presentation	26-28 July, 2013	2013 International Symposium on Biological Engineering and Natural Sciences (ISBENS), Bangkok
	National		
	Activity	Date (Month, Year)	Organizer
	Poster Presentation	22-23 June, 2011	16th National Conference on Medical & Health Sciences, Kota Bharu

PROBLEMS/CONSTRAINTS (If Any) (*Masalah/ Batasan, jika ada*)**F****RECOMMENDATION (*cadangan/Perambatan jika ada*)****F**

G Emerging new psychoactive substances impose public health implications worldwide, and include plants' phytochemicals such as Mitragynine (MG) from *Mitragyna speciosa* (or 'Ketum'). Studies have demonstrated the reciprocal interaction between endocannabinoid (ECB) system and opioid systems in the modulation of brain-reward and neurobiological mechanisms underlying drug addiction. To date the neurochemical basis of Ketum abuse potential remains elusive. This research attempted to implicate ECB system in the abuse liabilities of emerging psychoactive plant, Ketum and its opioid-like alkaloid, mitragynine (MG). We had demonstrated the locomotor and behavioural effects of MG-sensitised Swiss albino mice in IntelliCage® using an approach of context-independent sensitisation. Animals were later sacrificed for immunohistochemical localisation of CB1 receptor in the brain with confirmatory analysis using Western blotting of the brain homogenates. Adult Albino Swiss mice were subjected to experimental groups of MG alone; MG + NIDA-41020 (CB1 receptor antagonist); Morphine sulphate; Δ -9-Tetrahydrocannabinol + NIDA-41020; and vehicle. Daily intraperitoneal injection (i.p) of MG (5 to 25 mg/kg; 5mg/kg increment) at a 6-day interval was administered for 30 days, and plus once daily, 20mg NIDA-41020 (oral). Findings to date showed neuroadaptive chronic exposure of morphine, and works are in its final phase for comparison with MG and in the presence of CB1 antagonist. Data analysis to date provide supportive ground for the first time to our knowledge, to indicate the involvement of CB1 receptor as the neural target of Ketum misuse potential. (Two manuscripts in preparation for potential publication in indexed-journals).

Date : 6 Feb 2014

Tarikh

Project Leader's Signature:

Tandatangan Ketua Projek



COMMENTS, IF ANY ENDORSEMENT BY RESEARCH MANAGER/GRANTER (R/M/G)

(Komen, sekiranya ada endorsement oleh Pengerusi Projek / Pembiayai Projek)

H

Name:

Nama:

Date:

Tarikh:

13/3/14

Signature:

Tandatangan:



PROF. MADYA LEE KEAT TEONG

Pengarah
Pejabat Pengurusan & Kreativiti Penyelidikan
Universiti Sains Malaysia
11800 USM, Pulau Pinang.

JABATAN BENDAHARI
KUMPULAN WANG PENYELIDIKAN FUNDAMENTAL
PENYATA PERBELANJAAN SEHINGGA 31 DISEMBER 2013

Jumlah Geran	RM68,000.00	Ketua Projek	DR MUZAIMI MUSTAPHA
Peruntukan (Tahun 1) 2011	RM40,320.00	Tajuk Projek	CB1 CANNABINOID RECEPTOR IN BRAIN MESOLIMBIC SYSTEM OF MITRAGYNINE-SENSITISED ALBINO WISTAR RATS AS A CANDIDATE MOLECULAR TARGET IN MITRAGYNA SPECIOSA (KETUM) ADDICTION
Peruntukan (Tahun 2) 2012	RM27,680.00		
		Tempoh	30 BULAN (01/04/2011-30/09/2013)
		No. Akaun	203/PPSP/6171132

Kwgan	Akaun	PTJ	Projek	Peruntukan Projek	Perbelanjaan Terkumpul sehingga Tahun lalu	Peruntukan Semasa	Tanggungan Semasa	Bayaran Tahun Semasa	Belanja Tahun Semasa	Baki Projek
203	11000 PPSP		6171132	28,800.00	12,938.18	15,861.82	-	11,835.01	11,835.01	4,026.81
203	14000 PPSP		6171132			-	-		-	-
203	15000 PPSP		6171132	-		-	-		-	-
203	21000 PPSP		6171132	5,500.00	5,045.20	454.80			-	454.80
203	22000 PPSP		6171132	-		-	-		-	-
203	23000 PPSP		6171132			-	-		-	-
203	24000 PPSP		6171132		24.00	(24.00)			-	(24.00)
203	26000 PPSP		6171132			-	-		-	-
203	27000 PPSP		6171132	29,300.00	20,471.92	8,828.08	4,192.00	8,205.28	12,397.28	(3,569.20)
203	28000 PPSP		6171132			-			-	-
203	29000 PPSP		6171132	4,400.00	2,726.50	1,673.50		1,298.20	1,298.20	375.30
203	35000 PPSP		6171132			-			-	-
203	A11102 PPSP		6171132	-	628.95	(628.95)			-	(628.95)
203	A11559 PPSP		6171132	-	-	-			-	-
				68,000.00	41,834.75	26,165.25	4,192.00	21,338.49	25,530.49	634.76



Contents lists available at ScienceDirect

Neuroscience and Biobehavioral Reviews

Journal homepage: www.elsevier.com/locate/neubiorev

Review

From Kratom to mitragynine and its derivatives: Physiological and behavioural effects related to use, abuse, and addiction

Zurina Hassan^{a,1}, Mustapha Muzaimi^{b,1}, Visweswaran Navaratnam^a, Nurul H.M. Yusoff^a,
Farah W. Suhaimi^a, Rajakumar Vadivelu^a, Balasingam K. Vicknasingam^a, Davide Amato^c,
Stephan von Hörsten^d, Nurul I.W. Ismail^b, Nanthini Jayabalan^b, Ammar I. Hazim^a,
Sharif M. Mansor^a, Christian P. Müller^{c,*}

^a Centre for Drug Research, Universiti Sains Malaysia, 11800 Minden, Penang, Malaysia^b Department of Biomedicine, School of Medical Sciences, Universiti Sains Malaysia, Health Campus, 16250 Kubang Kerbau, Kelantan, Malaysia^c Department of Psychiatry and Psychotherapy, Friedrich-Alexander-University Erlangen-Nuremberg, Schwabachanlage 6, 91054 Erlangen, Germany^d Franz-Personat Center, Exper. Mental Therapy, Friedrich-Alexander-University Erlangen-Nuremberg, Germany

ARTICLE INFO

Article history:

Received 6 August 2012

Received in revised form 8 October 2012

Accepted 22 November 2012

Keywords:

Kratom

Ketum

Mitragyna speciosa

Mitragynine

7-Hydroxymitragynine

Analgesia

Abuse

Addiction

ABSTRACT

Kratom (or Ketum) is a psychoactive plant preparation used in Southeast Asia. It is derived from the plant *Mitragyna speciosa* Korth. Kratom as well as its main alkaloid, mitragynine, currently spreads around the world. Thus, addiction potential and adverse health consequences are becoming an important issue for health authorities. Here we reviewed the available evidence and identified future research needs. It was found that mitragynine and *M. speciosa* preparations are systematically consumed with rather well defined instrumentalization goals, e.g. to enhance tolerance for hard work or as a substitute in the self-treatment of opiate addiction. There is also evidence from experimental animal models supporting analgesic, muscle relaxant, anti-inflammatory as well as strong anorectic effects. In humans, regular consumption may escalate, lead to tolerance and may yield aversive withdrawal effects. Mitragynine and its derivatives actions in the central nervous system involve μ -opioid receptors, neuronal Ca^{2+} channels and descending monoaminergic projections. Altogether, available data currently suggest both, a therapeutic as well as an abuse potential.

© 2012 Elsevier Ltd. All rights reserved.

Contents

1. Introduction	139
2. Botanical origin	139
3. Preparation of plants and consumption	139
4. Medical use	140
5. Epidemiology	141
6. Legal status	141
7. Phytochemistry	141
8. Pharmacokinetic	142
9. Metabolism and detection	142
10. Toxicology	143
11. Pharmacology	144
11.1. Receptor interactions	144
11.2. Cellular effects	144
12. Physiological effects	144
12.1. Antinociceptive effects	144

* Corresponding author at: Section of Addiction Medicine, Department of Psychiatry and Psychotherapy, Friedrich-Alexander-University Erlangen-Nuremberg, Schwabachanlage 6, Erlangen 91054, Germany. Tel.: +49 0 9131 85 36806.
E-mail address: Christian.Mueller@uk-erlangen.de (C.P. Müller).

¹ These authors contributed equally.

Title: Use of the IntelliCage system to assess the behavioural effects in Swiss albino mice following chronic morphine treatment

Authors: Nurul Hossain Wan Ismail, Nandhini Jayabalan, Muzaimi Mustapha

Affiliations: Department of Neurosciences, School of Medical Sciences, Universiti Sains Malaysia, Health Campus, 16150 Kubang Kerian, Kelantan.

ABSTRACT

Background/Objective: Morphine, being the most efficacious and widely prescribed opioid, is subjects to abuse liability. Adaptive changes in neurons are a hallmark of chronic morphine treatment and are related to altered behaviours associated with morphine dependence and withdrawal syndrome. Studies had shown the possibility of learning and memory interference with chronic morphine exposure. However, multi-dimensional study of animal models of morphine addiction remains scarce. To address this issue experimentally, we performed a longitudinal study using the IntelliCage automated learning system, which allows the detailed analysis of mouse behaviour in social groups.

Method: Male Swiss albino mice were randomly assigned to either the control ($n=6$) or morphine-treated group ($n=6$). Mice were subjected to a 28-day regimen with morphine sulphate (5 mg/kg, s.c.). Control animals received an equal volume of saline (1 ml/kg) and were administered intraperitoneally (i.p.). The IntelliCage were used as the setting for the context-independent behavioural sensitisation to observe exploratory behaviours and cognitive performances of the animals. Protocols covering circadian exploration, motivation for natural reward with/without air-puff punishment, place learning and reversal place learning were used for longitudinal characterisation of behaviour.

Results: Differences in exploratory activities were significant where the morphine group showed behavioural inflexibility and shifted circadian rhythms compared with their baseline activity and the control group ($P<0.05$). Overall, both groups showed significant increment in lick preference at sucrose reward corner ($P<0.001$), where the morphine group had significantly higher preference for sucrose corner than control group ($P<0.05$). Both groups showed significant reduction in the number of visits to the sucrose reward corner when it was associated with an air-puff punishment ($P<0.001$). However, no significance difference was observed between morphine and control group in their resistance to punishment ($P>0.05$), as measured by the reduction in sucrose consumption despite air-puff punishment. In the place